USFDA issued a warning letter to Glenmark Pharmaceuticals for significant CGMP violations at its Pithampur plant, including failing to establish laboratory controls and adequate testing programs.

S&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing ...

Glenmark Pharmaceuticals is set to become net cash positive through its licensing agreement with AbbVie Inc. This move aims ...

The US health regulator has pulled up Glenmark Pharmaceuticals for manufacturing lapses, including failure to establish laboratory controls, at its Pithampur-based plant.      In a warning letter, the ...

Pharma giants like Cipla, Glenmark, and Emcure are stepping into the booming skincare market, challenging beauty brands with ...

Choice Institutional Equities has reiterated its positive stance on Glenmark Pharma following a major licensing deal between ...

Glenmark Pharma's licensing deal with AbbVie will make it cash positive, improving its financial position and liquidity, according to S&P.

Indian stock market benchmarks—the Sensex and the Nifty 50—ended lower on Friday, 18 July, extending losses for the third ...

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the company to reconsider the drug’s future. The Phase III study (NCT06400511) ...

On 21 July 2025, the Court of Appeal delivered a significant ruling in AstraZeneca AB & Anor v Generics (UK) Limited & Ors, ...

Firms downgrade 2025 outlook, isocyanate start-up launches, hydrogen projects advance, and more ...